Importantly, ex vivo DDC-treated primary CLL patient samples showed a significant increase in S473pAKT (Fig. 6G), in conjunction with downstream increase in T163pMcl-1 and Mcl-1 (Fig. 4J). This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.